Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03643055` - 18F-Fluorocholine PET/CT in Medullary Thyroid Cancer
Terminated	`NCT02709889` - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT06277180` - 68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC	N/A
Withdrawn	`NCT04760288` - A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).	Phase 3
Not yet recruiting	`NCT06079723` - A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study
Recruiting	`NCT01739634` - The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer	Phase 1/Phase 2
Recruiting	`NCT03157128` - A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)	Phase 1/Phase 2
Completed	`NCT02856347` - Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin	N/A
Completed	`NCT03037385` - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT04280081` - A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation	Phase 2
Not yet recruiting	`NCT06292988` - Predictive Factors for Medullary Thyroid Cancer Aggressiveness
Completed	`NCT01757470` - Vandetanib Risk Minimisation Effectiveness	N/A
Recruiting	`NCT03899792` - A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors	Phase 1/Phase 2
Recruiting	`NCT01660984` - Natural History Study of Children and Adults With Medullary Thyroid Cancer
Withdrawn	`NCT03838692` - Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer	Phase 2
Terminated	`NCT02363647` - Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer	N/A
Terminated	`NCT00582712` - An Initial Study of Lithium in Patients With Medullary Thyroid Cancer	Phase 2
Recruiting	`NCT06141369` - Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)	N/A
Completed	`NCT06243965` - Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma?
Active, not recruiting	`NCT01298323` - Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment	Phase 3

NCT number	NCT05830500
Study type	Interventional
Source	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact
Status	Recruiting
Phase	Phase 4
Start date	June 19, 2023
Completion date	December 2028

Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms